ASX ANNOUNCEMENT **13 September 2023**

CHIMERIC ANNOUNCES AGREEMENT TO SUPPORT PHASE 1B CLINICAL TRIAL FOR CHM 0201 IN NEWLY DIAGNOSED AML

- **Investor webinar with the Principal Investigator of the trial, Dr Abhishek Maiti, to be held at 11am AEST Thursday 14 September. Register here.**

Sydney, Australia, 13 September 2023: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, today announced the execution of a clinical study agreement with The University of Texas MD Anderson Cancer Center to support the "ADVENT-AML" Phase 1B study, in which Chimeric's off-the-shelf universal donor NK cell therapy CHM 0201 will be evaluated in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

The ADVENT-AML (NCT05834244) study is designed to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following completion of a dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.

ADVENT-AML will be the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care of Azacitidine with Venetoclax (AZA-VEN). As the trial progresses beyond dose confirmation, it will also be the first trial to evaluate cellular therapy in newly diagnosed AML patients.

The study, which has received IND clearance by the FDA and is expected to open to enrollment at MD Anderson by year end 2023, will be led by Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at MD Anderson.

Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with a median age at diagnosis between 65-72 years. Despite treatment advances, patients who are not eligible for intensive chemotherapy or allogeneic stem cell transplant patients have limited therapeutic options. Outcomes for these high-risk subgroups are poor with median overall survival (mOS) of 6 to 9 months in the newly diagnosed setting[1] and 2.4 months for patients with relapse or refractory disease[2]. Consequently, novel therapies are urgently needed to improve outcomes for patients with AML.

"This exciting new clinical trial aligns with the emerging evidence that cell therapies provide the best clinical outcomes in the earliest line of treatment," said Jason B Litten, MD, Chief Medical Officer of Chimeric Therapeutics.

"By combining CHM 0201 with the current standard of care for AML patients we may be able to significantly enhance the outcomes for these patients."

Under the terms of the clinical study agreement, Chimeric will provide CHM 0201 study drug as well as partial financial support for study. In addition to the modest financial support from Chimeric, the study will be supported by grant funding from multiple funding sources including Gateway for Cancer Research.

Webinar with Dr Abhishek Maiti

Chimeric is pleased to host a webinar regarding this announcement and Phase 1B trial for shareholders and interested parties.

Chimeric's CEO and Managing Director Jennifer Chow, Chief Medical Officer Dr Jason B. Litten and the trial's Principal Investigator Dr Abhishek Maiti will host the session. An opportunity to ask questions will also be provided.

When: 11am AEST, Thursday 14 September 2023
Register at: https://us02web.zoom.us/webinar/register/WN_a3sxS_C6T2Gz-4cZWnIbGw

Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Chimeric's website and social media channels.

Questions can be sent in advance of the webinar to matt@nwrcommunications.com.au

1. DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. *Lancet Haematol.* 2020;7:e724-36
2. Maiti A, Rausch CR, Cortes JE, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. *Haematologica*. 2021;106(3):894–898.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy

pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Initial positive data from the investigator-initiated phase 1A trial has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating

safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au